Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mary Beth, Jones"'
Autor:
José Baselga, Marianne Ewertz, Scot Ebbinghaus, Christine K. Gause, Joanne L. Blum, Antoinette R. Tan, Serafin Morales, Mary Beth Jones, Kumudu Pathiraja, Beverly Moy, Tufia C. Haddad, Ellie Im, Hope S. Rugo, Javier Cortes, David J. Mauro, Ahmad Awada, L Eaton, Eva Ciruelos, Kathryn J. Ruddy, Peter Vuylsteke
Publikováno v:
Breast cancer research and treatment, vol 163, iss 3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Baselga, J, Morales, S M, Awada, A, Blum, J L, Tan, A R, Ewertz, M, Cortes, J, Moy, B, Ruddy, K J, Haddad, T, Ciruelos, E M, Vuylsteke, P, Ebbinghaus, S W, Im, E, Eaton, L, Pathiraja, K, Gause, C K, Mauro, D, Jones, M B & Rugo, H S 2017, ' A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer ', Breast Cancer Research and Treatment, vol. 163, no. 3, pp. 535–544 . https://doi.org/10.1007/s10549-017-4199-3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Baselga, J, Morales, S M, Awada, A, Blum, J L, Tan, A R, Ewertz, M, Cortes, J, Moy, B, Ruddy, K J, Haddad, T, Ciruelos, E M, Vuylsteke, P, Ebbinghaus, S W, Im, E, Eaton, L, Pathiraja, K, Gause, C K, Mauro, D, Jones, M B & Rugo, H S 2017, ' A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer ', Breast Cancer Research and Treatment, vol. 163, no. 3, pp. 535–544 . https://doi.org/10.1007/s10549-017-4199-3
PurposeCombining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0c820c9a4a3dd16d5dbc64f6079bd5
https://doi.org/10.1007/s10549-017-4199-3
https://doi.org/10.1007/s10549-017-4199-3
Autor:
Yu-Jung Wei, Regina Bussing, Xinyue Liu, Mary Beth Jones, Almut G. Winterstein, Nikhil P. Rao, Marie McPherson
To examine incidence of adverse health outcomes and associated factors among preschoolers (under age 6) who received antipsychotic treatment through the Florida Medicaid Prior Authorization (PA) program.Using Florida's PA registry linked to the state
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d78d53314eaad0f651fb5c5f445f4461
https://europepmc.org/articles/PMC5824663/
https://europepmc.org/articles/PMC5824663/
Autor:
Noemia Afonso, Antonino Musolino, L Eaton, José Baselga, Ellie Im, Marta Ferreira, Zhen Wang, Serafin Morales, Christine K. Gause, Antoinette R. Tan, Olivier Tredan, Joanne L. Blum, Andrew Denker, Mario Campone, Hope S. Rugo, Mary Beth Jones, Javier Cortes, David J. Mauro, Kyong Hwa Park, Jungsil Ro
Publikováno v:
Breast cancer research and treatment, vol 165, iss 3
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
PurposeTo evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012ef3a906b37326705916f88c1e4740
https://pubmed.ncbi.nlm.nih.gov/28681171
https://pubmed.ncbi.nlm.nih.gov/28681171
Autor:
Hagop M. Kantarjian, Clayton D. Knox, Raoul Tibes, Ivana Gojo, Farhad Ravandi, Craig Fancourt, Amy O. Johnson-Levonas, Raymond L. H. Lam, Shelonitda Rose, Mary Beth Jones, Mark D. Minden, Payal Shah Patel, Mrinal M. Patnaik
Publikováno v:
Leukemia research. 48
Objective Evaluate safety/tolerability/efficacy of MK-8242 in subjects with refractory/recurrent AML. Methods MK-8242 was dosed p.o. QD (30–250 mg) or BID (120–250 mg) for 7on/7off in 28-day cycle. Dosing was modified to 7on/14off, in 21-day cycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::073a147272212bd5e2de79d7d48cc4d9
https://pubmed.ncbi.nlm.nih.gov/27544076
https://pubmed.ncbi.nlm.nih.gov/27544076
Autor:
Susan Jentz, Mary Beth Jones, Robert J. Constantine, Michael A. Bengtson, Ross Andel, Marie McPherson
Publikováno v:
Pharmacoepidemiology and Drug Safety. 21:152-160
Purpose This study aims the following: (i) to describe the exposure to antipsychotic medications over a 4‐year period experienced by a cohort of children who initiated antipsychotic treatment before their sixth birthday; and (ii) to identify variab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d18fca871bd19ed1e655eccffffe3679
https://doi.org/10.1002/pds.2189
https://doi.org/10.1002/pds.2189
Autor:
Robert J, Constantine, Susan, Jentz, Michael, Bengtson, Marie, McPherson, Ross, Andel, Mary Beth, Jones
Publikováno v:
Pharmacoepidemiology and drug safety. 21(2)
This study aims the following: (i) to describe the exposure to antipsychotic medications over a 4-year period experienced by a cohort of children who initiated antipsychotic treatment before their sixth birthday; and (ii) to identify variables associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e4e45c65c79a84c2658337da2edc9b9f
https://pubmed.ncbi.nlm.nih.gov/21793097
https://pubmed.ncbi.nlm.nih.gov/21793097